Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic,multi-national,Latin American lupus cohort
Restricted accessResearch articleFirst published online August, 2019
Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic,multi-national,Latin American lupus cohort
The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE).
Methods
A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed.
Results
Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20–37) years and 47.8 (17.9–68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48–0.99; p = 0.0440) was protective, while doses of prednisone >15 and ≤60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69–10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35–16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10–2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01–1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11–1.34; p < 0.0001) were predictive factors of serious infections.
Conclusions
Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients.
MakACheungMWChiewHJLiuYHoRC. Global trend of survival and damage of systemic lupus erythematosus: Meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum2012; 41: 830–839.
3.
UrowitzMBBookmanAAKoehlerBEGordonDASmytheHAOgryzloMA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med1976; 60: 221–225.
4.
TektonidouMGWangZDasguptaAWardMM. Burden of serious infections in adults with systemic lupus erythematosus: A national population-based study, 1996–2011. Arthritis Care Res (Hoboken)2015; 67: 1078–1085.
5.
Pons-EstelBACatoggioLJCardielMH, et al.The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics’. Medicine (Baltimore)2004; 83: 1–17.
6.
ShinjoSKBonfaEWojdylaD, et al.Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum2010; 62: 855–862.
7.
SisoARamos-CasalsMBoveA, et al.Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus2008; 17: 281–288.
8.
HerrintonLJLiuLGoldfienRMichaelsMATranTN. Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J Rheumatol2016; 43: 1503–1509.
9.
Ruiz-IrastorzaGOlivaresNRuiz-ArruzaIMartinez-BerriotxoaAEgurbideMVAguirreC. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther2009; 11: R109–R109.
10.
Teh C, Wan S, Ling G. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol 2018; 37: 2081–2086.
11.
FeldmanCHHirakiLTWinkelmayerWC, et al.Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol2015; 67: 1577–1585.
12.
BoschXGuilabertAPallaresL, et al.Infections in systemic lupus erythematosus: A prospective and controlled study of 110 patients. Lupus2006; 15: 584–589.
13.
Rúa-FigueroaILopez-LongoJGalindo-IzquierdoM, et al.Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum2017; 47: 38–45.
14.
TanEMCohenASFriesJF, et al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
17.
GladmanDGinzlerEGoldsmithC, et al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
18.
DanzaARuiz-IrastorzaG. Infection risk in systemic lupus erythematosus patients: Susceptibility factors and preventive strategies. Lupus2013; 22: 1286–1294.
19.
DuffyKNDuffyCMGladmanDD. Infection and disease activity in systemic lupus erythematosus: A review of hospitalized patients. J Rheumatol1991; 18: 1180–1184.
20.
PetriMGenoveseM. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: A prospective study of the Hopkins Lupus Cohort. J Rheumatol1992; 19: 1559–1565.
21.
JeongSJChoiHLeeHS, et al.Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis2009; 41: 268–274.
22.
Zonana-NacachACamargo-CoronelAYanezPSanchezLJimenez-BalderasFJFragaA. Infections in outpatients with systemic lupus erythematosus: A prospective study. Lupus2001; 10: 505–510.
23.
GladmanDDUrowitzMBKagalAHallettD. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol2000; 27: 377–379.
24.
Ugarte-GilMFAcevedo-VasquezEAlarconGS, et al.The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Ann Rheum Dis2015; 74: 1019–1023.
25.
Abu-ShakraMUrowitzMBGladmanDDGoughJ. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol1995; 22: 1265–1270.
26.
Eudy AH, Fu D, Fang Q, Hong Petri M. Infection as a Predictor of Organ System Damage Accrual and/or Death in Systemic Lupus Erythematosus. Arthritis & Rheumatism 2011; 63: 1392.
27.
Ruiz-IrastorzaGDanzaAKhamashtaM. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford)2012; 51: 1145–1153.
28.
Merayo-ChalicoJGomez-MartinDPineirua-MenendezASantana-De AndaKAlcocer-VarelaJ. Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: A case–control study. QJM2013; 106: 451–457.
29.
Gonzalez-EchavarriCCapdevilaOEspinosaG, et al.Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: Data from the RELES cohort. Lupus2018; 27: 2253–2261.
30.
CondonMBAshbyDPepperRJ, et al.Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis2013; 72: 1280–1286.
31.
ZeherMDoriaALanJ, et al.Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus2011; 20: 1484–1493.
32.
Fischer-BetzRChehabGSanderO, et al.Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: A prospective observational study. J Rheumatol2012; 39: 2111–2117.
33.
Ruiz-IrastorzaGUgarteASaint-Pastou TerrierC, et al.Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev2017; 16: 826–832.
34.
Van VollenhovenRFMoscaMBertsiasG, et al.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis2014; 73: 958–967.
35.
Van VollenhovenRVoskuylABertsiasG, et al.A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis2017; 76: 554–561.
36.
FranklynKLauCSNavarraSV, et al.Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis2016; 75: 1615–1621.
37.
Pons-EstelBABonfaESorianoER, et al.First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis2018; 77: 1549–1557.
38.
NoelVLortholaryOCasassusP, et al.Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis2001; 60: 1141–1144.
39.
BadshaHKongKOLianTYChanSPEdwardsCJChngHH. Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus2002; 11: 508–513.
40.
BultinkIEHamannDSeelenMA, et al.Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res Ther2006; 8: R183–R183.
41.
AlarconGSMcGwinGBertoliAM, et al.Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis2007; 66: 1168–1172.
42.
Pimentel-QuirozVRUgarte-GilMFPons-EstelGJ, et al.Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Semin Arthritis Rheum2017; 47: 199–203.
43.
BruceINO’KeeffeAGFarewellV, et al.Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis2015; 74: 1706–1713.
44.
RolainJMColsonPRaoultD. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents2007; 30: 297–308.
45.
SavarinoABoelaertJRCassoneAMajoriGCaudaR. Effects of chloroquine on viral infections: An old drug against today’s diseases?Lancet Infect Dis2003; 3: 722–727.
46.
LertchaisatapornKKasitanonNWangkaewSPantanaSSukitawutWLouthrenooW. An evaluation of the association of leukopenia and severe infection in patients with systemic lupus erythematosus. J Clin Rheumatol2013; 19: 115–120.
47.
NgWLChuCMWuAKChengVCYuenKY. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM2006; 99: 37–47.
48.
CarliLTaniCVagnaniSSignoriniVMoscaM. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact – A systematic literature review. Semin Arthritis Rheum2015; 45: 190–194.
49.
FaddahSElwakdMAboeleneinAHusseinM. Lymphopenia and systemic lupus erythematosus, a preliminary study: Correlation with clinical manifestations, disease activity and damage indices. The Egyptian Rheumatologist2014; 36: 125–130.
50.
AlarconGSCalvo-AlenJMcGwinGJr, et al.Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis2006; 65: 1168–1174.
